How to Dose MOTS-c

The Body Pharm MOTS-c pen is titrated from the lowest setting upward, not started at a fixed research dose. Begin at 0.2 mg for the first two weeks so your body adjusts to the product, then step up 0.2 mg at a time — 0.4 mg, 0.6 mg, 0.8 mg, 1 mg — no more often than every two weeks, and only when your energy is good and the previous dose is well tolerated. If a dose leaves you fatigued or crashing, you hold at that dose until you feel normal on it before going any higher. Delivery is subcutaneous via 30–32G, 4–6 mm insulin-style needles [1][5][6]. No completed peer-reviewed phase-1/2 human trial with a full dosing table has been published as of 2026, so every parameter below reflects Body Pharm product guidance plus rodent work and clinic practice, not licensed therapeutic guidance [8].

Key Takeaways

• Start at 0.2 mg for the first two weeks to let your body get used to the product, then titrate up in 0.2 mg steps (0.4, 0.6, 0.8, 1 mg) no faster than every two weeks
• Only increase when your energy is good and the current dose is fully tolerated; if a dose gives you fatigue or a crash, hold there until you feel normal on it before going higher
• The characteristic sign you have moved up too fast is the post-workout crash: energy through your session, then a heavy crash 3–4 hours later — that means your body is not used to the dose yet
• Common timing is one injection about 30 minutes before the gym, so the energy lands during your session
• AMPK activation persists for 48–72 hours post-injection, so dosing every day is redundant and can blunt the effect
• Subcutaneous injection into abdominal or thigh sites using 30–32G needles is the standard delivery route
• MOTS-c remains unlicensed in the UK with no MHRA marketing authorisation; all dosing parameters are research-only extrapolations and Body Pharm product guidance, not medical advice

Titration at a glance

The two-week minimum per step is a floor, not a target. If a dose leaves you fatigued or crashing, stay on it until you feel normal on that dose — however many weeks that takes — before considering the next step. MOTS-c remains an unlicensed research peptide in the UK with no MHRA marketing authorisation [8].

What Is MOTS-c and Why Does Dosing Matter?

MOTS-c is a 16-amino-acid mitochondria-derived peptide encoded by the mitochondrial 12S rRNA gene, with a molecular weight of approximately 2,174 Da [6]. Lee and colleagues first characterised it in 2015 (Cell Metabolism) as a systemic regulator of metabolic homeostasis in mouse models. It acts through the AMPK (adenosine monophosphate-activated protein kinase) pathway to mimic an energy-deficit signal similar to exercise or caloric restriction [6][7].

Mechanistically, MOTS-c disrupts folate-cycle methionine and purine metabolism. This raises the AICAR (5-aminoimidazole-4-carboxamide ribonucleotide) pool and triggers AMPK phosphorylation. That cascade upregulates mitochondrial biogenesis, GLUT4 (glucose transporter type 4) trafficking, and fatty-acid oxidation in skeletal muscle [6][7]. The signal is upstream and metabolic rather than receptor-mediated in the classical GPCR (G protein-coupled receptor) sense, which is why dosing logic differs from peptides like the GHRH (growth hormone-releasing hormone) analogues.

Why precision matters

The AMPK response is both dose- and frequency-dependent. Too little produces no measurable effect; too much, too fast produces the crash pattern researchers report — a strong energy lift followed by a heavy slump hours later as the system over-corrects. Titrating upward slowly lets the body adapt to each level of the energy-stress signal before the next increase. Continuous high-frequency administration risks attenuating the very energy-stress signalling that makes the peptide useful. AMPK is a sensor that adapts to chronic activation [7], so repeated exposure without rest windows blunts the metabolic signal.

This is why the practical protocol starts as low as 0.2 mg and climbs in small 0.2 mg steps: each step is only taken once the previous one is comfortable, so you find the level your body tolerates rather than overshooting it [6][7].

As of 2026, no large-scale human RCT (randomised controlled trial) for MOTS-c has been completed or published with full dosing tables, so every parameter discussed here is extrapolated from preclinical work and clinic practice [8]. The same research-only caveats apply across the broader mitochondrial-peptide cluster, including how to dose NAD+ and tissue-repair compounds such as GHK-Cu.

The Body Pharm Titration Protocol at a Glance

The Body Pharm approach starts everyone low and moves up slowly. You begin at 0.2 mg per injection for the first two weeks purely to let your body get used to the product, then step up 0.2 mg at a time — 0.4 mg, 0.6 mg, 0.8 mg, 1 mg — with at least two weeks on each step, moving up only when your energy is good and the dose is fully tolerated.

Two weeks per step is the minimum, not the goal. Increase only if your energy is good and you are not getting the crash described below. If a step gives you fatigue or a crash, you stay on that dose — not the next one — until you feel completely normal on it, and only then consider moving up. This is Body Pharm product guidance and a summary of off-label research/clinic practice, not medical advice or an MHRA-approved dosing standard [1][8]. Researchers stacking mitochondrial-pathway compounds may reference how to dose NAD+ for comparative scheduling logic.

Timing Around Training and the Crash Rule

Most users take their MOTS-c injection about 30 minutes before the gym. The energy lift lands during the session, which is the point at which you want it.

The key thing to watch for comes afterwards. If you get good energy for your workout and then a big crash 3–4 hours later, that crash is the signal that your body is not yet used to the dose. It is not a reason to push through or to increase — it is the opposite. When you get that crash:

• Do not increase the dose. Stay exactly where you are.
• Hold at that dose until the crash stops and you feel normal through the whole day on it — not just during the workout.
• Only once a dose gives you clean energy with no later crash should you consider stepping up by the next 0.2 mg.

Some people settle comfortably at 0.6 mg or 0.8 mg and never need 1 mg. The right dose is the highest step you tolerate with steady energy and no crash, reached slowly — not the top of the range reached quickly.

Why 2–3× Per Week? The Pharmacodynamic Rationale

MOTS-c is dosed 2–3× per week — in practice, on training days, about 30 minutes before the gym — because AMPK activation from a single dose persists for an estimated 48–72 hours in preclinical models before signalling returns to baseline [2]. Daily dosing would be redundant and potentially desensitising. Spacing injections at least 48 hours apart preserves the energy-stress signal AMPK is meant to mimic, this is the mechanism the peptide was characterised around in Lee et al.'s original 2015 mouse-model work [2]. Whatever your dose on the titration ladder, the every-other-day spacing stays the same; you titrate the dose, not the frequency.

The pharmacodynamic logic is fairly straightforward. MOTS-c interferes with the folate cycle and purine biosynthesis, raising AICAR and triggering AMPK phosphorylation. This upstream energy-sensor response then drives mitochondrial biogenesis and insulin-sensitivity changes downstream [2]. Because those transcriptional and metabolic effects accumulate over days, dosing into an already-active AMPK pool adds little signal and risks blunting receptor responsiveness. No published study has time-resolved that activation window in hours with clinical precision, so the 48–72-hour estimate is extrapolated from repeated-dose rodent endpoint assays rather than human PK/PD (pharmacokinetic/pharmacodynamic) curves [2].

Preclinical models show no additional benefit from dosing more frequently than every 48 hours, and daily administration actually reduces the metabolic response compared to spaced dosing [2].

Contrast with daily-dosed peptides

MOTS-c diverges from peptides such as BPC-157, which target localised tissue-repair pathways with short biological half-lives and therefore benefit from daily or twice-daily administration. MOTS-c is a systemic metabolic signal, not a wound-site agent, so frequency tracks the downstream pathway's reset time, not plasma half-life.

Why 4 weeks on, 2 weeks off

Continuous administration in mouse models shows diminishing metabolic response after roughly four weeks of uninterrupted dosing [2]. That is the periodisation rationale behind the 2-week washout. The rest window allows AMPK sensitivity and mitochondrial transcriptional machinery to reset before the next cycle.

Researchers comparing scheduling logic across mitochondrial-pathway compounds can cross-reference how to dose NAD+; those running tissue-repair stacks may consult how to dose GHK-Cu for contrast.

Reconstitution: You Don't Reconstitute the Body Pharm Pen

The Body Pharm MOTS-c pen ships already reconstituted — a pre-mixed, ready-to-inject solution. There is nothing to mix, no bacteriostatic water to add, no vial to prepare. Keep it refrigerated (2–8 °C), fit a fresh pen needle, dial the dose you are on, and inject. If you are using the pen, you can skip the rest of this section — it dials directly in the titration steps (0.2, 0.4, 0.6, 0.8, 1 mg) with no volume maths at the point of use.

The steps below are general reference for the lyophilised (freeze-dried) vial format — the older way some research peptides still ship as a dry powder you rehydrate yourself. They do not apply to the Body Pharm pen; they are here only for researchers working from a powder vial rather than a pre-filled pen.

Work through the sequence below in a clean area with washed hands:

1. Gather materials: the lyophilised peptide vial, bacteriostatic water (0.9% benzyl alcohol), alcohol swabs, and a sterile transfer syringe with a drawing needle.
2. Swab the septum of both the BW and peptide vials with an alcohol swab and let them air-dry for approximately 30 seconds.
3. Draw the BW volume specified for your vial into the transfer syringe.
4. Inject the BW slowly down the inner wall of the vial. Never aim the stream directly at the powder cake, as turbulent impact can shear the peptide.
5. Swirl gently between the fingers until fully dissolved. Do not shake; agitation foams the solution and degrades peptide integrity.
6. Rest for 2–3 minutes. The solution must be clear and colourless before use; discard if cloudiness or particulates appear.
7. Refrigerate and use within the vial's in-use window (see below).

For a self-reconstituted vial, bacteriostatic water is preferred over plain sterile water because the 0.9% benzyl alcohol suppresses microbial growth across the ~28-day in-use window typical for a hand-mixed multi-dose vial. (This 28-day window is the vial format, not the Body Pharm pen — the sealed pre-filled pen carries a 24-month unopened / 12-month in-use shelf life; see Storage below.)

Pen dial reference

The pen is dialled straight to the titration step you are on — you never convert a dose into a volume by hand:

Move the dial up one step only when the current step is fully tolerated and gives you clean energy with no later crash. Researchers stacking with mitochondrial cofactors can cross-reference reconstitution mechanics in the how to dose NAD+ guide, and those preparing copper-peptide solutions in parallel should consult how to dose GHK-Cu for compatibility notes.

Subcutaneous Injection Technique and Site Rotation

Subcutaneous (SC) injection into abdominal or thigh adipose tissue is the dominant route for MOTS-c in human-adjacent research protocols, with intramuscular administration appearing only in selected preclinical rodent work [2][5]. SC delivery gives slower, more consistent absorption than IM (intramuscular) and matches the pen-based workflow most UK researchers are using in 2026.

Reported Pinch-and-Inject Parameters

1. Site preparation. Protocols describe cleaning the site with a 70% isopropyl swab and allowing it to dry fully.
2. Skin fold. A 2–3 cm fold of skin and subcutaneous fat is typically pinched between thumb and forefinger.
3. Needle angle. Reported angles are 90° for a 4–6 mm pen needle, or 45° where a longer 8 mm needle is used in a lean site.
4. Administration rate. Slow depression of the pen plunger over 5–10 seconds is described in the literature.
5. Dwell time. A 10-second hold before withdrawal is reported to prevent leak-back at the needle track.
6. Withdrawal. Protocols describe releasing the skin fold and applying light pressure with dry gauze; massaging the site is not recommended.

Body Pharm UK pen cartridges are compatible with standard 30–32G, 4–6 mm pen needles, which is the de facto standard for adult SC peptide injection in the UK [5].

Site rotation map

Rotating across at least four to six distinct sites per weekly schedule prevents lipohypertrophy, the fibrofatty thickening that develops with repeated injection at one point and progressively distorts absorption kinetics.

Keep a simple rotation log (date, site, dose, batch) so that no single point receives a repeat injection within 7–10 days. Researchers running parallel mitochondrial-pathway compounds should keep separate site rosters for each peptide; the same site-rotation logic applies to the workflows covered in how to dose NAD+ and how to dose GHK-Cu.

MOTS-c Cycling: 4 Weeks On, 2 Weeks Off

A 4-week active / 2-week rest cycle is the most defensible MOTS-c periodisation framework for research use in 2026. Metabolic readouts in rodent models plateau after roughly four weeks of continuous administration, consistent with AMPK pathway adaptation and downstream receptor desensitisation [6][8]. The 2-week washout allows signalling sensitivity to reset before the next exposure block.

No published human cycling RCT for MOTS-c exists as of 2026 [8]. The periodisation logic below is extrapolated from preclinical continuous-versus-intermittent dosing patterns in mouse models and from clinic-practice schedules running 8–12 week windows [1][6][8].

A standard 12-week research window

Alternative: single 8-week block

Researchers running longer-interval endpoints (for example, HbA1c, VO₂max retest, body-composition imaging) often prefer a single 8-week active block followed by a 4-week rest. This consolidates exposure into one continuous window, which simplifies attribution when paired with a single pre/post measurement pair, at the cost of losing the within-study reset that a two-cycle design provides.

Cycle length should follow the research question, not the other way round. Short metabolic-flexibility studies fit the 4/2 pattern cleanly; mitochondrial biogenesis or endurance-adaptation questions may justify the 8/4 structure. Parallel pathway work using NAD+ or GHK-Cu should be cycled on independent calendars to keep variables isolated.

Storage, Handling, and Shelf Life

The Body Pharm MOTS-c pen ships already reconstituted — a pre-mixed solution in a sealed cartridge, not a lyophilised powder you rehydrate. Store it at 2–8 °C, protected from light. Sealed and unused (never pierced), the pen holds a 24-month shelf life. Once it has been pierced and used at least once, the in-use shelf life is 12 months — so date the pen at first use and finish it within that window. Do not freeze; freeze-thaw cycles drive aggregation and loss of bioactivity in small peptides. MOTS-c-specific published stability data remain limited as of 2026, so these figures reflect Body Pharm product handling plus standard peptide practice rather than compound-specific trials.

Quick-reference storage table

Handling and pen hygiene

Use clean technique on every draw: alcohol-swab the septum, fit a fresh needle, and minimise punctures to limit microbial ingress and coring fragments. Store the multi-dose pen refrigerated between uses with the needle cap on and the needle removed after each injection to prevent capillary leakage and air ingress.

Researchers running parallel protocols with NAD+ or GHK-Cu should label each pen clearly. Cross-confusion at the fridge is a common, avoidable protocol failure.

MOTS-c Stacking: Research Combinations to Know

MOTS-c is most commonly investigated alongside other mitochondrial- or longevity-targeted peptides where the mechanistic pathways are complementary rather than overlapping. As of 2026, no completed human trial has formally characterised pharmacokinetic interactions between MOTS-c and any co-administered peptide, so all stacking choices remain research-design questions, not therapeutic recommendations.

Documented research pairings

MOTS-c + NAD+ (or NMN/NR precursors). The logic is parallel mitochondrial support: MOTS-c activates AMPK and shifts substrate handling toward oxidative metabolism, whilst NAD+ precursors restore sirtuin-dependent signalling and electron-transport cofactor pools. No published 2024–2026 preclinical study has formally tested co-administration, so any synergy claim remains hypothetical. See the how to dose NAD+ guide for compatible scheduling.

MOTS-c + GHK-Cu. Researchers pair these where the question spans metabolic resilience and tissue-repair signalling, since GHK-Cu modulates copper-dependent remodelling pathways that sit outside MOTS-c's AMPK axis. Protocol notes are in the how to dose GHK-Cu guide.

MOTS-c + humanin. Both are mitochondria-derived peptides, and co-administration has appeared in preclinical ageing models exploring overlapping retrograde signalling [8].

MOTS-c + CJC-1295/Ipamorelin or SS-31. These appear in peptide-education protocols as "peak performance" stacks combining GH-axis or cardiolipin-targeted support with MOTS-c's energy-sensor activation [1][7].

Run one variable at a time if the goal is attributable data.

Frequently Asked Questions About MOTS-c Dosing

The questions below summarise the dosing variables most frequently raised by UK researchers working with MOTS-c in 2026. All answers reflect off-label research/clinic practice rather than MHRA-licensed therapeutic guidance.

How much MOTS-c should I take?

Start at 0.2 mg per injection for the first two weeks so your body gets used to the product, then titrate up in 0.2 mg steps — 0.4, 0.6, 0.8, 1 mg — with at least two weeks on each step. Only move up when your energy is good and the current dose is fully tolerated. Many people settle comfortably at 0.6–0.8 mg and never need 1 mg; the right dose is the highest step you tolerate with steady energy and no crash, reached slowly.

What if I get a crash after my workout?

That crash is the key signal to watch for. If you get good energy for the gym and then a big crash 3–4 hours later, your body is not yet used to the dose. Do not increase — hold at that dose until the crash stops and you feel normal on it through the whole day. Only once a dose gives you clean energy with no later crash should you step up by the next 0.2 mg.

Can MOTS-c be dosed daily?

Daily dosing is not standard at any step on the ladder. MOTS-c activates AMPK as an energy-deficit mimetic, and repeated-dose animal protocols sustain downstream mitochondrial signalling across 48–72 hours, making daily administration redundant in most research designs [2][7]. Space injections at least 48 hours apart — in practice, on training days — whatever titration step you are on.

How long does a MOTS-c cycle last?

Typical cycles run 4 weeks active followed by a 2-week washout, repeatable up to three cycles per year [4]. Within an active block you hold or advance your titration step by tolerance; you do not reset to 0.2 mg after each washout unless a long break has left you re-adjusting. Pair cycle planning with how to dose NAD+ if running parallel mitochondrial support.

What needle gauge suits MOTS-c subcutaneous injection?

A 29–31G needle at 8–12 mm length is the de facto standard for adult abdominal and thigh subcutaneous peptide administration in UK practice [5][7]. Insulin-pen-style 4–6 mm, 31–32G needles also deposit reliably into the subcutaneous layer and reduce discomfort during multi-week cycles. The same gauges suit how to dose GHK-Cu protocols.

Is MOTS-c the same as humanin?

No. MOTS-c and humanin are distinct mitochondrial-derived peptides encoded within the mitochondrial genome, with different amino acid sequences and partially overlapping but separate downstream pathways. MOTS-c primarily activates AMPK via folate-cycle disruption, whereas humanin acts through cytoprotective receptor signalling. Co-administration appears in preclinical ageing models exploring overlapping retrograde signalling [8].

Research Disclaimer and Regulatory Context (UK)

MOTS-c is sold strictly for research and analytical purposes only and is not approved for human use by the MHRA or any UK regulatory body as of 2026. It is not a licensed medicine in the United Kingdom and holds no marketing authorisation for any indication [1][2].

The Medicines and Healthcare products Regulatory Agency (MHRA) treats peptides without a marketing authorisation as unlicensed substances that cannot legally be promoted with therapeutic claims. MOTS-c does not appear on UK Misuse of Drugs schedules, placing it in a research-chemical category distinct from licensed pharmaceuticals [1]. Import and possession for laboratory use is permissible; administration to humans outside a registered clinical trial is not.

Body Pharm UK products are supplied for in vitro and laboratory research only and are not intended for human consumption. This guide is not medical advice and does not constitute instructions for human use. Researchers running parallel mitochondrial-pathway work on how to dose NAD+ or how to dose GHK-Cu are bound by the same regulatory framework.

Next Steps

Planning a MOTS-c research protocol typically begins by defining the primary endpoint (metabolic flexibility, mitochondrial biogenesis, endurance capacity, or other). The cycle structure (4/2 or 8/4) follows from that endpoint's measurement interval, with a site-rotation log and storage protocol established before reconstitution. For researchers stacking MOTS-c with complementary mitochondrial-pathway compounds, the how to dose NAD+ and how to dose GHK-Cu guides help align scheduling and avoid variable overlap. Documenting all doses, injection sites, and dates throughout the study supports reproducibility and informs future protocol refinement.

References

1. Clinic and vendor MOTS-c dosing protocols (2023–2025), 5–10 mg weekly research schedules. Practitioner practice, not a controlled trial. [unverified — no linkable source]
2. Lee C, et al. The Mitochondrial-Derived Peptide MOTS-c Promotes Metabolic Homeostasis and Reduces Obesity and Insulin Resistance. Cell Metab. 2015. pubmed.ncbi.nlm.nih.gov/25738459
3. Intensive/research MOTS-c dosing figures cited in vendor and clinic protocols. [unverified — no linkable source]
4. Pulse-dosing and per-year cycling conventions from practitioner MOTS-c protocols. [unverified — no linkable source]
5. Vendor injection-technique and needle-gauge conventions for subcutaneous MOTS-c. [unverified — no linkable source]
6. Lee C, et al. The Mitochondrial-Derived Peptide MOTS-c Promotes Metabolic Homeostasis and Reduces Obesity and Insulin Resistance. Cell Metab. 2015. pubmed.ncbi.nlm.nih.gov/25738459
7. Lee C, et al. The Mitochondrial-Derived Peptide MOTS-c Promotes Metabolic Homeostasis and Reduces Obesity and Insulin Resistance. Cell Metab. 2015. pubmed.ncbi.nlm.nih.gov/25738459
8. MOTS-c UK regulatory status (MHRA unlicensed-substance framework; no marketing authorisation) and 2025 blueprint/education summaries. Regulatory and practitioner context, not a peer-reviewed trial. [unverified — no linkable source]